ClinicalTrials.Veeva

Menu
U

Universitatsklinikum Essen | Ruhrlandklinik - Zentrum fur Schlaf- und Telemedizin

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Azacitidine
JNJ-56136379
JNJ-73763989
Lenalidomide
Daratumumab
Ustekinumab
Durvalumab
Dexamethasone
ONTAK
INCMGA00012

Parent organization

This site is a part of Universitatsklinikum Essen

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 77 total trials

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: tafasitamab
Drug: placebo

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimen...

Enrolling
Amyloidosis
Drug: Dexamethasone
Drug: Cyclophosphamide

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and...

Active, not recruiting
Colitis, Ulcerative
Drug: Matching Placebo
Drug: Ustekinumab Dose Based on BSA and Body Weight

This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at...

Enrolling
Muscular Atrophy, Spinal
Drug: Risdiplam

In this study, researchers will learn about a study drug called BIIB115 in healthy male volunteers and in participants with spinal muscular atrophy (...

Active, not recruiting
Muscular Atrophy, Spinal
Healthy Volunteer
Drug: BIIB115-Matching Placebo
Drug: BIIB115

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Drug: M281
Drug: Placebo

The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Ty...

Active, not recruiting
Anti-myostatin
Neuromuscular Manifestations
Drug: Apitegromab

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with...

Enrolling
Accelerated Phase Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Drug: Ponatinib

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic...

Active, not recruiting
Metastatic Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Drug: Cemiplimab
Biological: RP1

The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, an...

Active, not recruiting
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two...

Active, not recruiting
Duchenne Muscular Dystrophy
Other: Placebo
Genetic: PF-06939926

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Celgene logo
Gilead Sciences logo
Biogen logo
Incyte logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Takeda logo
Eisai logo
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems